Jiangsu Hengrui Pharmaceuticals (01276): SHR-2906 Injection Obtains Drug Clinical Trial Approval Letter.
Hengrui Medicine (01276) announced that its subsidiary Beijing Shengdi Pharmaceutical Co., Ltd. has recently received the Approved Letter of Drug Clinical Trial for SHR-2906 Injection from the National Medical Products Administration. Clinical trials will be conducted soon.
Jiangsu Hengrui Pharmaceuticals (01276) announced that its subsidiary, Beijing Shengdi Pharmaceutical Co., Ltd., recently received the drug clinical trial approval notification issued by the National Medical Products Administration for the SHR-2906 injection. The company will soon begin clinical trials.
SHR-2906 injection is a biopharmaceutical developed independently by the company. It is expected to have a synergistic effect on regulating glucose and lipid metabolism, controlling weight by reducing energy intake and promoting energy expenditure, as well as improving the metabolic environment in the body. It is expected to have clinical efficacy in the treatment of overweight and obesity. As of now, there are no similar drugs approved for market both domestically and internationally. The accumulated research and development investment for SHR-2906 injection is approximately 17.06 million yuan.
Related Articles
CMSC (06099) elected Ma Xiaoli as a staff representative director of the eighth board of directors.
GREENTOWN CHINA(03900): Greentown Management and China Communications Construction Group signed a project management framework agreement for 2025.
MEMESTRATEGY (02440) successfully completed the issue of approximately 49.04 million subscription shares.
CMSC (06099) elected Ma Xiaoli as a staff representative director of the eighth board of directors.
GREENTOWN CHINA(03900): Greentown Management and China Communications Construction Group signed a project management framework agreement for 2025.
MEMESTRATEGY (02440) successfully completed the issue of approximately 49.04 million subscription shares.
